Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSolutions Stock Dropped 30% in April

By Jason Hawthorne - May 4, 2021 at 4:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company went from hero to zero in the fight against COVID-19.

What happened

Shares of Emergent BioSolutions (EBS 2.54%) fell 30% in April, according to data from S&P Global Market Intelligence, after quality-control errors at one of the company's facilities ruined millions of doses of Johnson & Johnson's COVID-19 vaccine.

The purge was required after ingredients of another vaccine had contaminated the production area of J&J's shot.  

A COVID-19 vaccine production line

Image source: Getty Images.

So what

CEO Robert Kramer chalked the errors up to the complexity of manufacturing two biologic products in the same facility -- which he says the government directed -- and trying to produce tens of millions more doses than the facility was built for. Counter to that narrative, an investigator from the Food and Drug Administration (FDA) had flagged several problems last year, including with procedures intended to prevent contamination or mix-ups.

Now what

Management says the core business continues operating as planned. Before the issues, the company had been a key supplier in the pandemic, helping manufacture vaccines for both Johnson & Johnson and AstraZeneca. Now the government has directed Johnson & Johnson to take over the plant in question and pulled production of the AstraZeneca vaccine from the facility.

The episode could hinder Emergent's competitiveness in the future, but Kramer said the company hadn't lost any customers so far. Revenue climbed 78% year over year in the first quarter, and management is projecting 15% growth for 2021. That's after cutting guidance by 10% because of the hold on COVID vaccine production.

Both management and shareholders are hoping the company gets the green light to resume production soon. To do so, it will have to address the agency's findings. That includes the nine related to cross-contamination issues. For now, the stock trades at its cheapest multiple of sales since 2014. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$31.83 (2.54%) $0.79
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$10,754.00 (-0.43%) $-46.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.